ERBB2 and pancreatic neoplasm: PI3K pathway alterations including HER2 amplification, PI3KCA mutations or PTEN loss have been found to be associated with sensitivity to GDC0941 in breast cancer cell lines in vitro and in vivo [27]; however, the above genetic alternations are rarely present in pancreatic tumors [21].